Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-dNPM-1-TCR.1 in relapsed or refractory acute myeloid leukemia
NL-OMON60756Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2024
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of MB-dNPM1-TCR.1 in acute myeloid leukemia (AML), sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Primary endpoint(s). Started Aug 2024; status: recruiting.
02
Drugs
MB-dNPM1-TCR.1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60756.